Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo

 

Unsupported browser: Your browser does not meet modern web standards. See how it scores »

Doyle says it would not be “unrealistic” to imagine commercializing the detection system within five years. The biggest challenge ahead, he says, is developing a more practical detection system. To date, he and his colleagues have used a jerry-rigged ultraviolet microscope–a bulky, impractical system that costs tens of thousands of dollars–to detect and identify particle probes bound to their targets. “I don’t imagine that for bedside use, people are going to want a microscope in every single room,” says Pregibon. “We need detectors that are portable and robust and can withstand repeated use.”

Doyle and Pregibon predict that if they succeed, their system could play a role in the detection of disease but also in identifying DNA or protein signals indicating which therapies will be most successful for a given patient. In 2005 the Food and Drug Administration approved a microarray that does just that: the AmpliChip test produced by Swiss-based pharmaceutical maker Roche. The test probes for two genes that influence how drugs such as certain antidepressants break down, and it can therefore predict whether someone is at risk of an adverse reaction to the drug, or may not respond to the drug. That system’s high price has limited its use.

Still, Groves warns that there’s plenty of work ahead. “It is still the Wild West when it comes to microfluidics and automation,” he says. “There are a lot of drastically different concepts out there, some of which are being developed into products, and many of which fail. It’s hard to know what will prove to be an industry standard 10 years from now.”

Groves points out that in order to be practical, the detection device will need to be able to crunch through large volumes of particles without clogging or otherwise failing. “I wonder about the fidelity of the system if it must run tens of thousands of assays continuously,” he says.

Adam Singer, an emergency-medicine specialist at Stony Brook University whose research has confirmed the value of bedside diagnostics in speeding up treatment, offers another word of warning. Singer says that cheap multitarget tests like Pregibon’s will be of little use if more science isn’t done to nail down markers that are truly instructive. Most microarray tests developed to date, Singer says, provide “general direction” in diagnosing illness, but not much more. “We’re still quite a ways away from being able to apply these technologies clinically. Sometimes the technologies are more advanced than the knowledge and the evidence.”

0 comments about this story. Start the discussion »

Credit: Daniel Pregibon

Tagged: Biomedicine, cancer, MIT, genetics, diagnostics, Harvard

Reprints and Permissions | Send feedback to the editor

From the Archives

Close

Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me